Bepranemab (UCB0107)

Disease area studied Abbreviated title Phase Study ID Registry database Study results Plain language summary Publication (if available)
Mild Cognitive Impairment or Mild Alzheimer's Disease (AD) A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD) Phase 2 AH0003
Ongoing
NCT04867616
2020-005829-88
2023-506170-12-00
Progressive Supranuclear Palsy A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Phase 1 PSP002
Ongoing
NCT04658199
2024-510951-36-00